CCA
NBIX icon

Checchi Capital Advisers’s Neurocrine Biosciences NBIX Stock Holding History

Checchi Capital Advisers’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-99
Closed -$4K – 919
2016
Q2 		$4K Hold
99
– – ﹤0.01% 1446
2016
Q1 		$4K Buy
+99
New +$3.93K ﹤0.01% 1450

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Checchi Capital Advisers's NBIX Position: Q3 2016 in Review

Checchi Capital Advisers sold out of Neurocrine Biosciences (NBIX) in Q3 2016, closing a stake of 99 shares — an estimated $4K sold.

Checchi Capital Advisers first reported a position in NBIX in Q1 2016 and held it in 2 quarters. The position peaked at $4K in Q2 2016. 244 funds tracked by Wall St. Rank hold NBIX as of Q3 2016.

  • Checchi Capital Advisers reported no remaining Neurocrine Biosciences position as of Q3 2016 after selling out during the quarter.
  • Checchi Capital Advisers sold 99 Neurocrine Biosciences shares in Q3 2016, an estimated $4K.
  • Checchi Capital Advisers first reported a position in Neurocrine Biosciences in Q1 2016 and held it in 2 quarters.
  • Checchi Capital Advisers's Neurocrine Biosciences position peaked at $4K in Q2 2016.
  • 244 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2016.

Based on Checchi Capital Advisers's 13F filing for Q3 2016, filed 10 Nov 2016.